Sepsis Therapeutics Market (Drug Class: Aminoglycosides, Cephalosporin, Glycopeptide Antibiotics, Others; Route of Administration: Intravenous, Oral; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Description

Third-generation Drugs and Antimicrobial Therapy to Combat Septic Infections

The severity of the septic process and the extent of organ dysfunction in patients require immediate admission to an ICU in hospital. To avoid extreme fatalities and admission to ICUs, healthcare companies in the sepsis therapeutics market are developing efficacious fourth- and fifth-generation drugs.

Revenue of cephalosporin drugs is projected to be the highest in 2027, in the sepsis therapeutics market, with an estimated value of ~US$ 2.2 billion. Thus, to gain positive outcome via clinical trials, manufacturers are collaborating with researchers & scientists to develop effective cephalosporin drugs. As such, healthcare institutions are approaching the combination therapy with third-generation cephalosporin and a tetracycline analogue to treat vibrio vulnificus infection in patients. This therapy has been gaining prominence in the sepsis therapeutics market, since the combination works as an 'in vitro' bactericidal activity against vibrio vulnificus.

Healthcare professionals are increasingly adopting antimicrobial therapy to minimize the damage caused by infections to the gut microbiome. As such, healthcare providers in the sepsis therapeutics market are delivering the right balance between the utilization of antimicrobials and the clinical need for treating specific signs and symptoms in patients.

Immunometabolism Delivers Insights on New Therapeutic Targets

Healthcare companies in the sepsis therapeutics market are increasing research on immunometabolism, as insights on immune regulation are helping manufacturers develop efficacious drugs. Since the early detection and treatment of sepsis is critical, researchers are studying the body’s natural and innate response to various classes of drugs by studying immunometabolism. To gain further insights, healthcare companies are running clinical trials involving antibiotics, fluids, and dialysis, to ensure blood flow to the affected organs. They are also devising methods of surgical therapies to remove damaged tissues.

As such, healthcare companies in the sepsis therapeutics market are trying to identify new therapeutic targets that could potentially reduce inflammatory response in patients. They are increasing research via animal testing by introducing lipopolysaccharide (LPS) in mice to see if the molecule can suppress the severity of inflammatory response.

Judicious Prescriptions and New Antimicrobial Agents Reduce Drug Resistance

Antimicrobials have a rapid and long-lasting effect on septic infections. However, antimicrobial resistance to gram-positive infections (GPIs) is emerging as a major public health threat to patients, worldwide. The growing prevalence of multidrug-resistant bacteria in patients has led to increased morbidity and mortality rates. This has created the issue of escalated treatment costs and prolonged hospitalization stay for patients. This is why, healthcare companies in the sepsis therapeutics market are developing new antimicrobial agents to reduce the resistance of drugs against gram-positive infections.

Healthcare companies are expected to develop a robust healthcare value and supply chain in the Asia Pacific region, as it is predicted for fast growth in the sepsis therapeutics market. For instance, stakeholders in the sepsis therapeutics market have observed the growing prevalence of methicillin resistant staphylococcus aureus bacteria in Indian patients that has led to the heavy consumption of antibiotics. Thus, stakeholders in the sepsis therapeutics market are recommending judicious prescription of antimicrobial agents, implementation of antibiotic stewardship programs, and conformation to suitable antibiotic policies developed by health commissions to reduce the problem of drug resistance in patients

Analysts’ View of Sepsis Therapeutics Market

The sepsis therapeutics market is predicted to exponentially grow from a value of ~US$ 3.2 billion that was accounted in 2018, to a value of ~US$ 6 billion by 2027. Healthcare providers are practicing early therapeutic plasma exchange in cases of septic shock in patients. This method is considered medically safe, and effective for septic shock patients. They are also introducing high doses of vasopressors for rapid hemodynamic improvement and favorable changes in the cytokine profile for patients observed with septic shock. However, in the case of GPIs, adverse effects related to safety and tolerability towards drugs is an ongoing challenge for healthcare companies. To overcome this challenge, manufacturers should introduce new antimicrobial agents in efficacious fourth- and fifth-generation drugs.

Sepsis Therapeutics Market: Overview

The global sepsis therapeutics market for the historical year of 2017 and forecast period of 2019 to 2027, rise in investments in research & development and novel pipeline drugs are projected to boost the growth of the global sepsis therapeutics market during the forecast period.

The global sepsis therapeutics market generated ~US$ 3.2 Bn revenue in 2018, and is expected to expand at a CAGR of 7.5% from 2019 to 2027.

Novel Pipeline Drugs and Rise in Incidence Rate of Sepsis: A Key Driver

The geriatric population is prone to developing sepsis, and is expected to increase the patient pool across the world, which, in turn, is projected to drive the sepsis therapeutics market during the forecast period.

According to the United Nations University (UNU), the percentage of the world population above 65 years of age is anticipated to increase from 9% in 2010 to 16% by 2050.

Rise in the epidemiological burden of sepsis increases the demand for the development of drugs for the treatment of sepsis. This is likely to boost the growth of the sepsis therapeutics market.

Leading pharmaceutical companies are striving to address these unmet medical needs through new product development.

Asahi Kasei Corporation is planning to launch ART-123 by 2021 for the treatment of sepsis. The drug has shown positive results for phase III clinical trial for sepsis, which would support the advancement of drugs for phase IV studies.

New approval and commercialization of novel therapeutic drugs under clinical trial studies are projected to be a major driver of the global sepsis therapeutics market from 2019 to 2027.

Cephalosporin Drug Class Prominent

The cephalosporin segment dominated the global sepsis therapeutics market in 2018, and is expected to account for a major market share during the forecast period, as third-generation cephalosporins are commonly used to treat neonatal and infant sepsis. Cephalosporins also have the broadest gram-negative bacterial coverage. This is likely to drive the cephalosporin segment during the forecast period.

The others segment is projected to grow at significant CAGR during the forecast period. The use of combination therapy for the treatment of sepsis, such as cephalosporin plus an aminoglycoside, is a driving factor that is expected to propel the segment from 2019 to 2027.

Intravenous Administration Popular

The most common way to administer antibiotics is intravenously, as intravenous antibiotics reach tissues faster and at higher concentrations than oral antibiotics. The preference of the intravenous route for administration of drugs is expected to propel the segment during the forecast period.

North America to Dominate Global Sepsis Therapeutics Market

North America accounted for a major share of the global market in 2018, followed by Europe. The high prevalence and rise in incidence of sepsis in the U.S. and Canada, wide base of pharmaceutical companies in the U.S., and easy availability of drugs in the region were key factors responsible for the prominent share held by North America in the global sepsis therapeutics market in 2018.

According to a study published in the National Center for Biotechnology Information (NCBI), around 300 people per 100,000 individuals in the U.S. are affected by severe sepsis and septic shock

Europe was also an attractive market for sepsis therapeutics in 2018. High budget for research & development in the field of sepsis treatment and various initiatives taken by private and government institutions to promote awareness about sepsis are estimated to propel the market in Europe during the forecast period. Furthermore, well-established healthcare facilities, new product approvals, and commercialization and favorable medical reimbursement policies are anticipated to drive the market in the region.

The market in Asia Pacific is estimated to grow at a faster pace than other regions during the forecast period, due to increase in the focus on the development of healthcare infrastructure by public as well as private hospitals, along with a rise in the demand for novel therapeutics among a significant patient population. The sepsis therapeutics market in Asia Pacific is driven by a large pool of patients with sepsis in China and Japan, and rise in investments by leading players in the region for the establishment of distribution channels.

Global Sepsis Therapeutics Market: Competitive Landscape

Detailed profiles of the manufacturers of sepsis therapeutics have been provided in the report to evaluate their key product offerings, financials, business strategies, and recent developments.

Key players operating in the global sepsis therapeutics market include -

  • INOTREM S.A.
  • Mylan N.V.
  • Asahi Kasei Corporation
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • RegeneRx
  • Adrenomed AG
  • AtoxBio
  • Endacea, Inc.

Key Questions Answered in TMR’s Sepsis Therapeutics Market Study

  • What is the scope of growth of sepsis therapeutic companies in the pharmaceutical drugs sector?
  • What will be the Y-o-Y growth of the sepsis therapeutics market between the years 2019 and 2027?
  • What is the influence of the changing trends in the sepsis therapeutics market?
  • Will North America continue to remain the most profitable regional market for sepsis therapeutic providers?
  • Which factors will hamper the growth of the sepsis therapeutics market during the forecast period of 2019 to 2027?
  • Which are the leading companies in the global sepsis therapeutics market?

Segmentation of the Sepsis Therapeutics Market

Drug Class

  • Aminoglycosides
  • Cephalosporin
  • Glycopeptide Antibiotics
  • Others

Route of Administration

  • Intravenous
  • Oral

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sepsis Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Sepsis Therapeutics Market Analysis and Forecasts, 2017–2027

5. Market Outlook

    5.1. Regulatory Scenario 

    5.2. Pipeline Analysis

6. Global Sepsis Therapeutics Market Analysis and Forecasts, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2027

        6.3.1. Aminoglycosides

        6.3.2. Cephalosporin 

        6.3.3. Glycopeptide Antibiotics 

        6.3.4. Others 

    6.4. Market Attractiveness, by Drug Class 

7. Global Sepsis Therapeutics Market Analysis and Forecasts, by Route of Administration 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2027

        7.3.1. Intravenous 

        7.3.2. Oral

    7.4. Market Attractiveness, by Route of Administration 

8. Global Sepsis Therapeutics Market Analysis and Forecasts, by Distribution Channel 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2027

        8.3.1. Hospital Pharmacies 

        8.3.2. Retail Pharmacies 

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness, by Distribution Channel 

9. Global Sepsis Therapeutics Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness, by Region

10. North America Sepsis Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value  Forecast, by Drug Class, 2017–2027

        10.2.1. Aminoglycosides

        10.2.2. Cephalosporin 

        10.2.3. Glycopeptide Antibiotics 

        10.2.4. Others 

    10.3. Market Value Forecast, by Route of Administration, 2017–2027

        10.3.1. Intravenous 

        10.3.2. Oral

    10.4. Market Value  Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies 

        10.4.2. Retail Pharmacies 

        10.4.3. Online Pharmacies

    10.5. Market Value  Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Drug Class 

        10.6.2. By Route of Administration 

        10.6.3. By Distribution Channel 

        10.6.4. By Country

11. Europe Sepsis Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2027

        11.2.1. Aminoglycosides

        11.2.2. Cephalosporin 

        11.2.3. Glycopeptide Antibiotics 

        11.2.4. Others 

    11.3. Market Value Forecast, by Route of Administration, 2017–2027

        11.3.1. Intravenous 

        11.3.2. Oral

    11.4. Market Value  Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies 

        11.4.2. Retail Pharmacies 

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Drug Class 

        11.6.2. By Route of Administration 

        11.6.3. By Distribution Channel 

        11.6.4. By Country/Sub-region

12. Asia Pacific Sepsis Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2027

        12.2.1. Aminoglycosides

        12.2.2. Cephalosporin 

        12.2.3. Glycopeptide Antibiotics 

        12.2.4. Others 

    12.3. Market Value Forecast, by Route of Administration, 2017–2027

        12.3.1. Intravenous 

        12.3.2. Oral

    12.4. Market Value Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies 

        12.4.2. Retail Pharmacies 

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis 

        12.6.1. By Drug Class 

        12.6.2. By Route of Administration 

        12.6.3. By Distribution Channel 

        12.6.4. By Country/Sub-region

13. Latin America Sepsis Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2027

        13.2.1. Aminoglycosides

        13.2.2. Cephalosporin 

        13.2.3. Glycopeptide Antibiotics 

        13.2.4. Others 

    13.3. Market Value Forecast, by Route of Administration, 2017–2027

        13.3.1. Intravenous 

        13.3.2. Oral

    13.4. Market Value Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies 

        13.4.2. Retail Pharmacies 

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis 

        13.6.1. By Drug Class 

        13.6.2. By Route of Administration 

        13.6.3. By Distribution Channel 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Sepsis Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value  Forecast, by Drug Class, 2017–2027

        14.2.1. Aminoglycosides

        14.2.2. Cephalosporin 

        14.2.3. Glycopeptide Antibiotics 

        14.2.4. Others 

    14.3. Market Value Forecast, by Route of Administration, 2017–2027

        14.3.1. Intravenous 

        14.3.2. Oral

    14.4. Market Value  Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies 

        14.4.2. Retail Pharmacies 

        14.4.3. Online Pharmacies

    14.5. Market Value  Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis 

        14.6.1. By Drug Class 

        14.6.2. By Route of Administration 

        14.6.3. By Distribution Channel 

        14.6.4. By Country/Sub-region

15. Competitive Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Company Profiles

        15.2.1. Mylan N.V. 

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Product Portfolio

            15.2.1.3. SWOT Analysis

            15.2.1.4. Strategic Overview

            15.2.1.5. Financial Overview

        15.2.2. Asahi Kasei Corporation 

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Product Portfolio

            15.2.2.3. SWOT Analysis

            15.2.2.4. Strategic Overview

            15.2.2.5. Financial Overview

        15.2.3. Pfizer, Inc. 

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Product Portfolio

            15.2.3.3. SWOT Analysis

            15.2.3.4. Strategic Overview

            15.2.3.5. Financial Overview

        15.2.4. GlaxoSmithKline plc 

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Product Portfolio

            15.2.4.3. SWOT Analysis

            15.2.4.4. Strategic Overview

            15.2.4.5. Financial Overview

        15.2.5. RegeneRx

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Product Portfolio

            15.2.5.3. SWOT Analysis

            15.2.5.4. Strategic Overview

            15.2.5.5. Financial Overview

        15.2.6. Adrenomed AG 

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Product Portfolio

            15.2.6.3. Strategic Overview

        15.2.7. AtoxBio

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

        15.2.8. ENDACEA, INC. 

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Product Portfolio

            15.2.8.3. Strategic Overview

        15.2.9. INOTREM S.A 

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Product Portfolio

            15.2.9.3. Strategic Overview

Choose License Type

Checkout Inquiry Sample